$32.83
0.832.59%
Last update: 10:33 AM
15 minutes delayed
Comments
Loading...
Guardant Health
GHNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Guardant Health (NASDAQ:GH) Stock, Analyst Ratings, Price Targets, Forecasts
Guardant Health Inc has a consensus price target of $50.4 based on the ratings of 22 analysts. The high is $140 issued by SVB Leerink on February 24, 2022. The low is $27 issued by Raymond James on November 13, 2023. The 3 most-recent analyst ratings were released by B of A Securities, Goldman Sachs, and Guggenheim on July 18, 2024, July 17, 2024, and June 28, 2024, respectively. With an average price target of $36 between B of A Securities, Goldman Sachs, and Guggenheim, there's an implied 9.66% upside for Guardant Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Goldman Sachs
Guggenheim
Canaccord Genuity
Jefferies
1calculated from analyst ratings
Analyst Ratings for Guardant Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/18/2024 | Buy Now | 21.84% | B of A Securities | Michael Ryskin | $28 → $40 | Maintains | Buy | Get Alert |
| 07/17/2024 | Buy Now | -2.53% | Goldman Sachs | Matthew Sykes | $28 → $32 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 9.66% | Guggenheim | Subbu Nambi | → $36 | Upgrade | Neutral → Buy | Get Alert |
| 06/04/2024 | Buy Now | 15.75% | Canaccord Genuity | Kyle Mikson | $30 → $38 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | -2.53% | Jefferies | Tycho Peterson | → $32 | Initiates | → Buy | Get Alert |
| 05/24/2024 | Buy Now | 34.02% | Stephens & Co. | Mason Carrico | → $44 | Reiterates | Overweight → Overweight | Get Alert |
| 04/29/2024 | Buy Now | -8.62% | Canaccord Genuity | Kyle Mikson | $45 → $30 | Maintains | Buy | Get Alert |
| 04/24/2024 | Buy Now | -14.71% | Craig-Hallum | Alex Nowark | → $28 | Assumes | → Buy | Get Alert |
| 04/15/2024 | Buy Now | -14.71% | Goldman Sachs | Matthew Sykes | $32 → $28 | Maintains | Buy | Get Alert |
| 04/05/2024 | Buy Now | — | Guggenheim | Subbu Nambi | — | Reiterates | → Neutral | Get Alert |
| 02/26/2024 | Buy Now | -8.62% | Piper Sandler | David Westenberg | $40 → $30 | Maintains | Overweight | Get Alert |
| 02/23/2024 | Buy Now | 37.07% | JP Morgan | Julia Qin | $60 → $45 | Maintains | Overweight | Get Alert |
| 02/23/2024 | Buy Now | 37.07% | Canaccord Genuity | Kyle Mikson | $50 → $45 | Maintains | Buy | Get Alert |
| 01/30/2024 | Buy Now | 12.7% | Goldman Sachs | Matthew Sykes | $43 → $37 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 12.7% | Goldman Sachs | Matthew Sykes | $43 → $37 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | — | Guggenheim | Subbu Nambi | — | Initiates | → Neutral | Get Alert |
| 12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel | — | Initiates | → Peer Perform | Get Alert |
| 11/13/2023 | Buy Now | -17.76% | Raymond James | Andrew Cooper | → $27 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/08/2023 | Buy Now | 52.3% | Morgan Stanley | Shannon O'Callaghan | $55 → $50 | Maintains | Overweight | Get Alert |
| 10/23/2023 | Buy Now | 37.07% | Goldman Sachs | Matthew Sykes | $52 → $45 | Maintains | Buy | Get Alert |
| 10/20/2023 | Buy Now | 37.07% | Goldman Sachs | Matthew Sykes | $52 → $45 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | 52.3% | Citigroup | Patrick Donnelly | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/28/2023 | Buy Now | 3.56% | Bernstein | Eve Burstein | → $34 | Initiates | → Outperform | Get Alert |
| 09/27/2023 | Buy Now | 21.84% | Piper Sandler | David Westenberg | → $40 | Upgrade | Neutral → Overweight | Get Alert |
| 08/08/2023 | Buy Now | 21.84% | Piper Sandler | David Westenberg | $30 → $40 | Maintains | Neutral | Get Alert |
| 08/07/2023 | Buy Now | 67.53% | Morgan Stanley | Shannon O'Callaghan | $60 → $55 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 52.3% | Citigroup | Patrick Donnelly | $40 → $50 | Maintains | Buy | Get Alert |
| 05/26/2023 | Buy Now | 21.84% | Citigroup | Patrick Donnelly | → $40 | Upgrade | Neutral → Buy | Get Alert |
| 05/11/2023 | Buy Now | 82.76% | Morgan Stanley | Shannon O'Callaghan | $66 → $60 | Maintains | Overweight | Get Alert |
| 05/10/2023 | Buy Now | 67.53% | Credit Suisse | Dan Leonard | $60 → $55 | Maintains | Outperform | Get Alert |
| 05/01/2023 | Buy Now | — | OTR Global | — | — | Downgrade | Mixed → Negative | Get Alert |
| 03/09/2023 | Buy Now | 0.52% | Citigroup | Patrick Donnelly | $60 → $33 | Downgrade | Buy → Neutral | Get Alert |
| 03/03/2023 | Buy Now | 6.61% | Piper Sandler | David Westenberg | $50 → $35 | Maintains | Neutral | Get Alert |
| 02/27/2023 | Buy Now | 101.04% | Morgan Stanley | Shannon O'Callaghan | $73 → $66 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | 52.3% | BTIG | Mark Massaro | $60 → $50 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 82.76% | Canaccord Genuity | Kyle Mikson | $65 → $60 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 61.44% | Cowen & Co. | Max Masucci | $70 → $53 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 97.99% | JP Morgan | Julia Qin | $75 → $65 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | 82.76% | Credit Suisse | Dan Leonard | $70 → $60 | Maintains | Outperform | Get Alert |
| 02/21/2023 | Buy Now | 122.36% | Morgan Stanley | Tejas Savant | $80 → $73 | Maintains | Overweight | Get Alert |
| 02/16/2023 | Buy Now | 91.9% | Stephens & Co. | Mason Carrico | → $63 | Reiterates | → Overweight | Get Alert |
| 02/06/2023 | Buy Now | 37.07% | Goldman Sachs | Matthew Sykes | $70 → $45 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 9.66% | Scotiabank | Sung Ji Nam | → $36 | Initiates | → Sector Outperform | Get Alert |
| 11/18/2022 | Buy Now | 158.91% | JP Morgan | Julia Qin | $100 → $85 | Maintains | Overweight | Get Alert |
| 11/07/2022 | Buy Now | 174.14% | Stephens & Co. | Mason Carrico | $99 → $90 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 113.22% | Goldman Sachs | Matthew Sykes | $80 → $70 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 113.22% | Credit Suisse | Dan Leonard | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/01/2022 | Buy Now | 52.3% | Piper Sandler | David Westenberg | $65 → $50 | Downgrade | Overweight → Neutral | Get Alert |
| 10/19/2022 | Buy Now | 168.05% | Craig-Hallum | Alex Nowark | → $88 | Initiates | → Buy | Get Alert |
| 10/06/2022 | Buy Now | 201.55% | Stephens & Co. | Mason Carrico | → $99 | Initiates | → Overweight | Get Alert |
| 08/25/2022 | Buy Now | 143.68% | Credit Suisse | Dan Leonard | → $80 | Initiates | → Outperform | Get Alert |
| 08/08/2022 | Buy Now | 143.68% | Morgan Stanley | Tejas Savant | $85 → $80 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 143.68% | Goldman Sachs | Matthew Sykes | $90 → $80 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 97.99% | Piper Sandler | David Westenberg | → $65 | Initiates | → Overweight | Get Alert |
| 05/09/2022 | Buy Now | 158.91% | Morgan Stanley | Tejas Savant | $120 → $85 | Maintains | Overweight | Get Alert |
| 05/06/2022 | Buy Now | 204.6% | Citigroup | Patrick Donnelly | $120 → $100 | Maintains | Buy | Get Alert |
| 02/24/2022 | Buy Now | 250.29% | Wells Fargo | Dan Leonard | $150 → $115 | Maintains | Overweight | Get Alert |
| 02/24/2022 | Buy Now | 265.52% | Morgan Stanley | Tejas Savant | $125 → $120 | Maintains | Overweight | Get Alert |
| 02/24/2022 | Buy Now | 265.52% | Citigroup | Patrick Donnelly | $180 → $120 | Maintains | Buy | Get Alert |
| 02/24/2022 | Buy Now | 326.44% | SVB Leerink | Puneet Souda | $170 → $140 | Maintains | Outperform | Get Alert |
| 02/15/2022 | Buy Now | 280.75% | Morgan Stanley | Tejas Savant | $150 → $125 | Maintains | Overweight | Get Alert |
| 11/05/2021 | Buy Now | 417.82% | SVB Leerink | Puneet Souda | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Guardant Health (GH) stock?
The latest price target for Guardant Health (NASDAQ:GH) was reported by B of A Securities on July 18, 2024. The analyst firm set a price target for $40.00 expecting GH to rise to within 12 months (a possible 21.84% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Guardant Health (GH)?
The latest analyst rating for Guardant Health (NASDAQ:GH) was provided by B of A Securities, and Guardant Health maintained their buy rating.
When was the last upgrade for Guardant Health (GH)?
The last upgrade for Guardant Health Inc happened on June 28, 2024 when Guggenheim raised their price target to $36. Guggenheim previously had a neutral for Guardant Health Inc.
When was the last downgrade for Guardant Health (GH)?
The last downgrade for Guardant Health Inc happened on May 1, 2023 when OTR Global changed their price target from N/A to N/A for Guardant Health Inc.
When is the next analyst rating going to be posted or updated for Guardant Health (GH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Guardant Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Guardant Health was filed on July 18, 2024 so you should expect the next rating to be made available sometime around July 18, 2025.
Is the Analyst Rating Guardant Health (GH) correct?
While ratings are subjective and will change, the latest Guardant Health (GH) rating was a maintained with a price target of $28.00 to $40.00. The current price Guardant Health (GH) is trading at is $32.83, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.